logo
  

Swiss Re Says Global Insured Losses Of $144 Bln From Disaster Events In 2017

The latest sigma study from the Swiss Re Institute said that total global economic losses from natural and man-made disasters in 2017 were $337 billion, almost double the losses in 2016 and the second highest on record. Global insured losses from catastrophe events were $144 billion, the highest-ever recorded in a single year.

The highest losses came from three hurricanes - Harvey, Irma and Maria - that struck the US and the Caribbean in quick succession.

These hurricanes resulted in combined insured losses of $92 billion, making 2017 the second costliest North Atlantic hurricane season since 2005. Last year was also a
record year for wildfires. Major wildfires across the globe resulted in combined insurance losses of $14 billion, the highest ever.

In terms of sigma criteria, there were 301 catastrophes worldwide in 2017,
down from 329 in 2016. More than 11 000 people lost their lives or went missing in disaster events last year, and millions were left homeless. Natural catastrophes claimed more than 8 000 victims. A landslide and floods in Sierra Leone in mid-August took most lives, with 1 141 people declared dead or missing. Elsewhere, heavy monsoon rains and separate flood events led to more than 1 000 deaths across India, Nepal and Bangladesh.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT